Education
About Us
Working with TipRanks
Follow Us
Sera Prognostics, Inc. (SERA)
:SERA
SERA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.37 - $9.13
Previous CloseN/A
Volume57.63K
Average Volume (3M)480.22K
Market Cap
$92.30M
Enterprise Value$108.81M
Total Cash (Recent Filing)$46.20M
Total Debt (Recent Filing)$568.00K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 05, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding36,705,025
10 Day Avg. Volume83,252
30 Day Avg. Volume480,224
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue946.20
Enterprise Value/Gross Profit10.88K
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$2.00Price Target Upside-22.78% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Commercialization OpportunityThe company has a significant opportunity ahead with the commercialization of its PreTRM test.
Revenue Growth PotentialAnalysts see the potential for an inflection in volume and revenue growth as a matter of when and not if.
Bears Say
Guideline Inclusion ChallengeGuideline inclusion is a critical mid-term catalyst and SERA plans to publish PRIME with 2-3 additional publications which should enhance PreTRM's profile for guideline inclusion.
Long-Term Investment HorizonSignificant material revenue traction is several years away, suggesting a longer-term investment horizon.
Sera Prognostics News
SERA FAQ
What was Sera Prognostics, Inc.’s price range in the past 12 months?
Sera Prognostics, Inc. lowest stock price was $1.37 and its highest was $9.13 in the past 12 months.
What is Sera Prognostics, Inc.’s market cap?
Sera Prognostics, Inc.’s market cap is $92.30M.
When is Sera Prognostics, Inc.’s upcoming earnings report date?
Sera Prognostics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 90 days.
How were Sera Prognostics, Inc.’s earnings last quarter?
Sera Prognostics, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.225 by $0.065.
Is Sera Prognostics, Inc. overvalued?
According to Wall Street analysts Sera Prognostics, Inc.’s price is currently Overvalued.
Does Sera Prognostics, Inc. pay dividends?
Sera Prognostics, Inc. does not currently pay dividends.
What is Sera Prognostics, Inc.’s EPS estimate?
Sera Prognostics, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Sera Prognostics, Inc. have?
Sera Prognostics, Inc. has 36,705,025 shares outstanding.
What happened to Sera Prognostics, Inc.’s price movement after its last earnings report?
Sera Prognostics, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.225. Following the earnings report the stock price went down -11.667%.
Which hedge fund is a major shareholder of Sera Prognostics, Inc.?
Currently, no hedge funds are holding shares in SERA
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (-22.78% Downside)
$2.00 (-22.78% Downside)
Blogger Sentiment
Bullish
SERA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 63.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $156.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.22%
12-Months-Change
Fundamentals
Return on Equity
-41.36%
Trailing 12-Months
Asset Growth
31.48%
Trailing 12-Months
Company Description
Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
SERA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced outlook. While there are positive developments in Medicaid reimbursement and strategic headcount expansion, the company's revenue generation remains minimal, and net losses continue. The ACOG update aligns with the company's strategy, but uncertainties around the Prime Study publication timeline persist.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
$2.00
▼(-22.78% Downside)
Technical Analysis
Ownership Overview
7.88% Insiders
6.54% Mutual Funds
0.58% Other Institutional Investors
81.75% Public Companies and
Individual Investors